Abstract
In May 2008, alvimopan (Entereg; Adolor/GlaxoSmithKline), a peripherally acting μ-opioid receptor antagonist, was approved by the US FDA to accelerate the time to gastrointestinal recovery following bowel resection surgery. It is the first pharmacotherapy to be approved for this application.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Maron, D. J. & Fry, R. D. New therapies in the treatment of postoperative ileus after gastrointestinal surgery. Am. J. Ther. 15, 59–65 (2008).
Delaney, C. P. et al. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann. Surg. 245, 355–363 (2007).
Murphy, D. B. et al. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87, 765–770 (1997).
Zimmerman, D. M. et al. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J. Med. Chem. 37, 2262–2265 (1994).
Liu, S. S. et al. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin. Pharmacol. Ther. 69, 66–71 (2001).
Food and Drug Administration. FDA labelling information. FDA web site [online], (2008).
Taguchi, A. et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N. Engl. J. Med. 345, 935–940 (2001).
Delaney, C. P. et al. Clinical outcomes and resource utilization associated with laparoscopic and open colectomy using a large national database. Ann. Surg, 247, 819–824 (2008).
Senagore, A. J. & Delaney, C. P. A critical analysis of laparoscopic colectomy at a single institution: lessons learned after 1000 cases. Am. J. Surg. 191, 377–380 (2006).
Webster, L. Alvimopan, a peripherally acting μ-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137, 428–440 (2008).
Gershell, L. Adolor. (Cowen and Company, 24 July 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
C.P.D. is a consultant to Adolor, Tranzyme and Wyeth, and receives research funding from Adolor.
Rights and permissions
About this article
Cite this article
Delaney, C., Yasothan, U. & Kirkpatrick, P. Alvimopan. Nat Rev Drug Discov 7, 727–728 (2008). https://doi.org/10.1038/nrd2668
Issue date:
DOI: https://doi.org/10.1038/nrd2668
